Table 1.
The main characteristics of studies evaluating the performance of TE for detection of portal hypertension, clinically significant portal hypertension, and severe portal hypertension
| First author, public year, [Ref. no.] | Study design | Country | No. of index cases (sex M:F), mean age, years | Etiology | Prevalence of % (n) |
Child A (%) | BMI (kg/m2) | QUADAS score | TE cut-off (kPa) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PH ≥6 mm Hg | CSPH ≥10 mm Hg | Severe ≥12 mm Hg | PH | CSPH | Severe PH | ||||||||
| Vizzutti et al. [8] (2007) | Prospective | Italy | 61 (39:22), 55.6±11.7 | CLD (61 HCV) | 77.1 (47) | 57.4 (35) | 45.9 | 23±3 | 11 | ≥13.6 | ≥17.6 | ||
| Lemoine et al. [9] (2008) | Retrospective | France | 92 (64:28), 56.0±13.0 | CLD (44 HCV-related cirrhosis, 48 alcohol-related cirrhosis) | 80.4 (74) | 100 | NR | 13 | HCV | ||||
| HCV | 20.5 | ||||||||||||
| 77.0 (34) | alcoholic | ||||||||||||
| alcohol | 34.9 | ||||||||||||
| 83.3 (40) | |||||||||||||
| Bureau et al. [10] (2008) | Prospective | France | 150 (90:60), median: 55.0 (inter-quartile range: 45-65) | CLD (51 alcohol, 46 viral hepatitis, 7 alcohol + virus, 11 NASH, 10 autoimmune hepatitis, 6 cholestatic disease, 19 miscellaneous) | 51.3 (76) | 20.0 | 24.4 | 13 | 21.0 | ||||
| Sánchez‐ Conde et al. [11] (2011) | Prospective | Spain | 38 (24:14), 47.0 (range: 42-49) | CLD (38 HIV/HCVcoinfection) | 73.7 (28) | 60.5 (23) | 71.05 | NR | 10 | ≥14.0 | ≥23.0 | ||
| Carrión et al. [12] (2006) | Prospective | Spain | 124 (82:42), Median: 60 (range: 35-73) | HCV-infected liver transplant recipients HCV-LT | 46.0 (60) | 21.7 (27) | NR | Median: 25 (range: 17–35) | 12 | ≥8.74 | ≥18.0 | ||
| Reiberger et al. [13] (2012) | Prospective | Austria | 695 (497:198), 50±12 | CLD (390 viral hepatitis, 227 alcoholic liver disease, 31 autoimmune hepatitis, 47 nonalcoholic steatohepatitis) | 72.9 (366/502) | 55 (276/502) | NR | 23.1 | 12 | ≥8 | ≥18.0 | ≥20 | |
| alcoholic | alcoholic | alcoholic | |||||||||||
| ≥10 | ≥19 | ≥23 | |||||||||||
| Berzigotti et al. [14] (2013) | Prospective | Italy | 117 (82:35), 60±11 | CLD (78 HCV 11 HBV, 16 alcohol, 12 other) | 67 (78) | 88.0 | 26.8±4.7 | 12 | ≥13.6 | ≥21.1 | |||
| Llop et al. [15] (2012) | Prospective | Spain | 79 (60:19), 62.0 (range: 41-80) | CLD (52 HCV, 8 alcohol, 10 HBV, 4 hemochromatosis, 3 NASH, 2 cryptogenic) | 40.5 (32) | 100 | NR | 14 | ≥13.6 | ≥21 | |||
TE, transient elastography; M, male; F, female; PH, portal hypertension; CSPH, clinically significant PH; BMI, body mass index; QUADAS, Quality Assessment of Diagnostic Accuracy Studies; CLD, chronic liver disease; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; HIV, human immunodeficiency virus; NR, normal range; LT, liver transplantation; HBV, hepatitis B virus.